Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) shares declined 4.62 percent to close at $6.82 a share Monday. The stock traded between $6.59 and $7.0 on volume of 21.40 million shares traded. Analysts at Citigroup have recently downgraded the company’s rating to "sell" from "neutral". Shares of Ariad Pharmaceuticals have fallen approximately 65.0 percent over the past year.
Find out more about Ariad Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/ARIA
Hologic, Inc. (NASDAQ: HOLX) shares declined 2.39 percent to close at $21.66 a share Monday. The stock traded between $21.58 and $22.04 on volume of 3.78 million shares traded. Analysts at Morgan Stanley have recently downgraded the company’s rating to "equal weight" from "overweight". Shares of Hologic have gained approximately 5.0 percent over the past year.
Find out more about Hologic including full access to the free equity report at:
www.RDInvesting.com/HOLX
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares gained 2.79 percent to close at $75.50 a share Monday. The stock traded between $74.11 and $75.94 on volume of 1.70 million shares traded. Analysts at UBS have recently upgraded the company’s rating to "buy" from "neutral". Shares of Vertex Pharmaceuticals have gained approximately 65.0 percent over the past year.
Find out more about Vertex Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/VRTX
Ventas, Inc. (NYSE: VTR) shares increased 2.48 percent to close at $58.20 a share Monday. The stock traded between $57.13 and $58.66 on volume of 2.55 million shares traded. Analysts at RBC Capital Markets have recently upgraded the company’s rating to "top pick" from "outperform". Shares of Ventas have fallen approximately 10.0 percent over the past year.
Find out more about Ventas including full access to the free equity report at:
www.RDInvesting.com/VTR
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]